News | Left Atrial Appendage (LAA) Occluders | July 07, 2016

AtriCure Announces First Patient Enrolled in FROST Cryoanalgesia Study

FROST will evaluate cryoablation of peripheral nerves for the temporary management of post-operative pain with cryoICE probe

AtriCure, FROST cryoanalgesia study, William Beaumont Hospital Michigan, cryoICE system

July 7, 2016 — AtriCure Inc. announced the first patient has been enrolled in the FROST study at William Beaumont Hospital, Dearborn, Mich. This company-sponsored trial will evaluate intraoperative cryoanalgesia therapy using cryoablation in conjunction with standard of care (SOC) pain management compared to SOC alone.

The design of the trial is a prospective, 3:1 randomized trial including a total of up to 100 patients. The randomization will include up to 75 patients in the treatment arm (intraoperative cryoablation with AtriCure’s cryoICE system plus SOC), and up to 25 patients in the control arm (SOC alone). The study will include patients undergoing unilateral thoracotomy cardiac procedures and will evaluate pain scores and lung function recovery during hospital stay.

The primary objective of the study is to demonstrate that intraoperative intercostal cryoanalgesia in conjunction with SOC provides improved analgesic efficacy and faster, more complete recovery in patients undergoing unilateral thoracotomy cardiac procedures as compared to current SOC. Additional endpoints, such as ICU length of stay, total hospital length of stay, opioid consumption and long-term neurologic recovery will be gathered.

“In my experience, cryoanalgesia appears to result in improved pain management,” said Steven F. Bolling, M.D., professor of cardiac surgery at University of Michigan Medical Center. “Perhaps more importantly, patients seem to extubate sooner and seem to be ready for an earlier discharge. FROST will seek to confirm this effect at multiple cardiac surgery institutions.”

“I have continued to see the benefits of cryoanalgesia therapies in conjunction with minimally invasive mitral valve surgery,” stated Francis Shannon, M.D., cardiothoracic surgeon, Beaumont Health System. “The benefit for patients is quite significant, and I look forward to developing further evidence through participation in the FROST study.”

Participating centers in the study are the William Beaumont Hospital and the University of Michigan Medical Center, as well as Cleveland Clinic Foundation. The coordinating investigators for the FROST study are Shannon and Wei Lau, M.D., at William Beaumont Hospital. Andrea Trescot, M.D., past president of the American Society of Interventional Pain Physicians, is serving as scientific advisor for this trial.

“Today’s pain management options offer relief while patients are hospitalized, but do little to address pain post-discharge,” said Lau, professor of anesthesiology at Oakland University William Beaumont School of Medicine. “We have seen cryoanalgesia control pain and improve recovery post-operatively.”

For more information: www.atricure.com


Related Content

News | Atrial Fibrillation

April 18, 2024 — New evidence-based research calls into question the conventional three-month blanking period ...

Home April 18, 2024
Home
News | Atrial Fibrillation

March 28, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home March 28, 2024
Home
News | Atrial Fibrillation

February 27, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home February 27, 2024
Home
News | Atrial Fibrillation

February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial (NCT05883631), a study formally launched in ...

Home February 06, 2024
Home
News | Atrial Fibrillation

February 2, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home February 02, 2024
Home
News | Atrial Fibrillation

January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed ...

Home January 18, 2024
Home
News | Atrial Fibrillation

December 29, 2023 — Boston Scientific Corporation has initiated the AVANT GUARD clinical trial to evaluate the safety ...

Home December 29, 2023
Home
News | Atrial Fibrillation

December 26, 2023 — Pulse Biosciences, Inc., a company primarily focused on leveraging its novel and proprietary CellFX ...

Home December 26, 2023
Home
News | Atrial Fibrillation

December 22, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home December 22, 2023
Home
News | Atrial Fibrillation

December 14, 2023 — Medtronic plc, a global leader in healthcare technology, today announced that the United States Food ...

Home December 14, 2023
Home
Subscribe Now